Regenxbio (RGNX) Revenue (2014 - 2025)

Regenxbio's Revenue history runs 12 years deep, the most recent figure standing at $30.3 million for Q4 2025.

• In Q4 2025, Revenue rose 43.0% year-over-year to $30.3 million; the TTM figure through Dec 2025 stood at $170.4 million (up 104.54% YoY), while the FY2025 annual figure was $170.4 million, up 104.54% from the prior year.
• Revenue was $30.3 million for Q4 2025 at Regenxbio, up from $29.7 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $398.7 million in Q4 2021 to a low of $15.6 million in Q1 2024.
• Historically, Revenue has averaged $46.4 million across 5 years, with a median of $23.2 million in 2024.
• The sharpest annual moves came in 2021 and 2022: Revenue jumped 1758.96% in 2021, then slumped 92.14% in 2022.
• A 5-year view of Revenue shows it stood at $398.7 million in 2021, then plunged by 92.14% to $31.3 million in 2022, then dropped by 29.13% to $22.2 million in 2023, then decreased by 4.5% to $21.2 million in 2024, then surged by 43.0% to $30.3 million in 2025.
• The last three Revenue figures came in at $30.3 million (Q4 2025), $29.7 million (Q3 2025), and $21.4 million (Q2 2025), per Business Quant data.